Clinical Trials Directory

Trials / Completed

CompletedNCT01055171

Neuromodulation of Trauma Memories in PTSD & Alcohol Dependence

Treatment Implications of Trauma Memory Modulation for PTSD & Alcohol Dependence

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
44 (actual)
Sponsor
Medical University of South Carolina · Academic / Other
Sex
All
Age
18 Years – 100 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to examine the effect of propranolol versus placebo on craving, distress and cue reactivity to trauma and alcohol cues.

Detailed description

Summary and Synthesis: Epidemiological studies have established the occurrence of high rates of AD in persons with PTSD. Likewise, studies of alcohol/drug abuse treatment seekers have documented high rates of trauma exposure and PTSD. The high prevalence of PTSD/AD comorbidity is the cause of enormous human suffering, most of which either goes untreated or is resistant to treatment efforts. Both theory and research concerning the interface between these two disorders suggests that PTSD is associated with the initiation of excessive alcohol use and/or the development of AD by way of an escape/avoidance behavioral mechanism wherein escalating alcohol use is reinforced by its ability to dampen the negative emotions and arousal associated with PTSD. If PTSD is often a primary cause of the initiation and maintenance of AD, then clinical interventions that primarily impact PTSD should lead to significant improvements in craving for, and use of, alcohol. The findings of two recent treatment studies offer especially compelling support for this expectation. Drawing on both basic neuroscience research and a developing body of suggestive clinical/applied research, we were led to consider if the putative memory modulating properties of the adrenergic antagonist propranolol might have therapeutic benefits for PTSD/AD comorbid individuals. Thus, the proposed study will test the hypothesis that the strategic administration of propranolol coupled with the elicitation/retrieval of trauma-related memories will dampen emotional distress, alcohol craving and cue reactivity during subsequent exposure to trauma- and alcohol-related cues. A two-week follow-up laboratory session and clinical assessment will permit us to evaluate whether treatment benefits are maintained over time and if there are any changes in alcohol use and PTSD symptomatology.

Conditions

Interventions

TypeNameDescription
DRUGPropranolol40 mg; Single Administration.
DRUGPlacebo40 mg; Single Dose.

Timeline

Start date
2010-01-01
Primary completion
2012-08-01
Completion
2012-08-01
First posted
2010-01-25
Last updated
2016-03-08
Results posted
2014-05-19

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01055171. Inclusion in this directory is not an endorsement.